drugset / Trial / NCT03036306

Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions

NCT03036306 ↗

Phase 1 Completed 24 enrolled ScarX Corp
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and local tolerability of two different concentrations of of SCX-001 cream, as compared to placebo, when topically applied twice a day for 21 days to artificially induced dermal wounds in healthy volunteers. In addition, the absorption and elimination of profiles of this topically applied product will be determined through pharmacokinetic sampling. Assessments for effect of SCX-001 vs. placebo will be done but are considered exploratory.

Timeline

Start
2017-01
Primary completion
2017-10-02
Completion
2017-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SCX-001 Unknown 1 % Topical
Subject SCX-001 Unknown 3 % Topical

Indications

No indication recorded.